均瑶健康(605388) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 395,905,330.07, representing a decrease of 11.10% compared to the same period last year[5]. - Net profit attributable to shareholders of the listed company was CNY 26,150,321.80, an increase of 9.34% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 23,794,077.50, reflecting a growth of 28.20% compared to the previous year[5]. - The basic earnings per share for the period remained at CNY 0.06, unchanged from the previous year[5]. - In Q1 2024, the company's net profit reached CNY 25,691,096.53, a slight increase from CNY 25,089,016.23 in Q1 2023, representing a growth of 2.4%[24]. - The total revenue for Q1 2024 was CNY 34,518,629.33, compared to CNY 33,477,682.25 in Q1 2023, indicating a year-over-year increase of 3.1%[24]. - Operating profit for Q1 2024 was CNY 34,344,130.23, up from CNY 33,559,160.01 in the same period last year, reflecting a growth of 2.3%[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,287,357,753.55, down 8.60% from the end of the previous year[6]. - The total assets as of March 31, 2024, were CNY 2.29 billion, a decrease of 8.6% from CNY 2.50 billion as of December 31, 2023[19]. - The total liabilities decreased to CNY 354.27 million in Q1 2024, down 37.9% from CNY 569.85 million in Q4 2023[20]. - The company's total equity as of March 31, 2024, was CNY 1.93 billion, slightly up from CNY 1.93 billion at the end of 2023[21]. Cash Flow - The net cash flow from operating activities was negative at CNY -129,488,834.36, with no applicable percentage change due to the nature of the data[5]. - The cash flow from operating activities showed a net outflow of CNY -129,488,834.36 in Q1 2024, worsening from CNY -92,212,326.92 in Q1 2023[28]. - Cash and cash equivalents at the end of Q1 2024 were CNY 225,990,046.68, down from CNY 347,527,068.94 at the end of Q1 2023[29]. - The company reported a significant decrease in cash received from sales, totaling CNY 301,006,032.17 in Q1 2024, compared to CNY 435,936,870.69 in Q1 2023, a decline of 30.9%[27]. - Investment activities resulted in a net cash outflow of CNY -78,431,446.71 in Q1 2024, compared to CNY -225,900,560.30 in Q1 2023, showing an improvement in cash flow management[28]. - The total cash outflow from financing activities was CNY 25,738,935.67 in Q1 2024, compared to CNY 1,510,000.00 in Q1 2023, indicating increased financing costs[29]. Shareholder Information - The top ten shareholders held a total of 32.66% and 24.18% of shares, respectively, with significant pledges on their holdings[10]. - The company's repurchase account holds 2,850,000 shares, accounting for 0.66% of the total share capital as of the reporting period[12]. Business Strategy and Development - The company integrated the domestic probiotic leader Junyao Runying, aiming to transform its business model over the next three to five years[14]. - The company is focusing on optimizing and upgrading existing products to enhance product strength and market competitiveness[13]. - The company is committed to becoming a global leader in probiotics, with a strategic vision to break the foreign monopoly in fermented food and beverages[13]. - The company has established a comprehensive "R&D-production-sales" integrated chain in the probiotic industry, facilitating effective industry layout[12]. - The company’s traditional business of ambient yogurt continues to expand its product categories and optimize existing products[15]. - The company’s probiotic business has shown significant growth, driven by capacity enhancement and competitive advantages in overseas markets[12]. - The company has developed a unique production process for its ambient lactic acid bacteria beverages, enhancing its competitive edge in the market[16]. - The company is focusing on the promotion and application of proprietary functional strains, which is expected to drive product upgrades and optimize overall business competitiveness[16]. Research and Development - The company's R&D expenses increased to CNY 7.33 million in Q1 2024, up 88.5% from CNY 3.88 million in Q1 2023, indicating a strong focus on innovation[23]. - The company's fermentation agent production line has been selected for the 2023 Shanghai Dairy Industry Advantageous Characteristic Industry Cluster Project[15]. Profitability and Cost Management - The company has enhanced its product cost structure, resulting in a noticeable recovery in gross profit margin compared to 2023[15]. - The total operating costs for Q1 2024 were CNY 363.85 million, down 13.2% from CNY 419.22 million in Q1 2023[23]. - The weighted average return on net assets increased by 0.10 percentage points to 1.34%[5].